Amycretin
Novo Nordisk's single-molecule GLP-1 + amylin co-agonist. Phase 1/2 in oral and subcutaneous formulations. The pharmacological consolidation of the Semaglutide + Cagrilintide concept into one peptide.
Amycretin: Novo Nordisk's single-molecule GLP-1 + amylin co-agonist. Phase 1/2 in oral and subcutaneous formulations. The pharmacological consolidation of the Semaglutide + Cagrilintide concept into one peptide. Amycretin is Novo Nordisk's experiment in putting Semaglutide and Cagrilintide together as one molecule instead of two separate drugs.
Amycretin is Novo Nordisk's experiment in putting Semaglutide and Cagrilintide together as one molecule instead of two separate drugs. Activates GLP-1 + amylin in a single injection. They're testing both an oral pill and a weekly injection. Phase 1/2 only, not available yet.
Investigational. Phase 1/2 trials by Novo Nordisk in oral and subcutaneous formulations.
Trial access only.
Who it's for
- →Trial participants in obesity studies
- →Followers of Novo's next-generation pipeline
- →Educational reference for dual co-agonist design
What to expect
- Week 1
Appetite drops. Some early-trial users reported faster onset than Semaglutide alone.
- Week 4
First titration step.
- Week 8
Phase 1b data showed weight loss outperforming Semaglutide-monotherapy comparators.
Looking at Amycretin? Your next 3 steps
- 1Work out your exact dose
Vial size + BAC water turns into the exact units to draw for Amycretin.
Open calculator → - 2See what to stack & monitor
The companion supplements and the bloodwork worth tracking on this kind of protocol.
Bloodwork guide → - 3Save it & ask the Coach
A free account saves your stack; membership adds the stack-aware AI Coach.
Create free account →
How it works (mechanism)
Single-molecule co-agonist, activates GLP-1 AND amylin receptors simultaneously. Pharmacological consolidation of the CagriSema concept into one peptide instead of two.
Dosing protocol
Stacks well with
Side effects
When NOT to use
- ⚠MTC / MEN-2 history
- ⚠Pancreatitis history
- ⚠Pregnancy / nursing
Bloodwork to monitor
- • Lipid panel
- • A1C
- • ALT/AST
Common mistakes
- • Expecting trial-grade material from community vendors
- • Treating it as available-now (Phase 1/2 still)
- • Comparing oral form dosing to sub-q form dosing
Drug & supplement interactions
- ⚠Combined GLP-1 + amylin warnings: insulin dose reduction; slowed oral absorption
- ⚠Trial-only, full interaction profile not yet published
New to Amycretin? Grab the starter checklist.
Drop your email and we'll send the one-page first-cycle starter checklist, plus a heads-up if Amycretin changes legal status. No account needed.
No spam. No selling your email. Just the checklist and the occasional reclassification alert.
Ask the Coach anything about Amycretin or your own stack. This is it working.
Trained only on Pepdex content. Does the dose math, flags interactions, knows your stack. Won't push vendors, won't pretend to be a doctor.
Get the Coach, $7.99/mo →Frequently asked
What is Amycretin?+
Is Amycretin FDA approved?+
Is Amycretin legal?+
Is Amycretin banned by WADA?+
Are you still natty after taking Amycretin?+
Do doctors prescribe Amycretin?+
What's the typical dose of Amycretin?+
What are the side effects of Amycretin?+
How long until Amycretin starts working?+
What can you stack with Amycretin?+
Where do people get Amycretin?+
More in Fat Loss
Strong weight loss with a cleaner side effect profile than semaglutide. A dual agonist (GLP-1 + GIP), FDA-approved as Mounjaro / Zepbound.
The original weight-loss wave, sold as Ozempic / Wegovy. A GLP-1 agonist.
Triple agonist (GLP-1 + GIP + glucagon) from Eli Lilly. In trials it outperforms Tirzepatide for weight loss.
Daily GLP-1 receptor agonist. FDA-approved 2010 (Victoza, T2D) and 2014 (Saxenda, obesity). The first wave of modern GLP-1 weight-loss therapy and direct predecessor to Semaglutide.